Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 1998

View Archived Issues

Novel PTK-related technology from Genentech and collaborators

Preclinical pharmacology of ebselen described in depth

ProCyte reports results from U.K. leg ulcer study

Calanolide A well tolerated in phase I trials

Tiazac approved for angina in U.S.

Warner-Lambert presents SAR for potent, nonpeptide HIV protease inhibitor at AIDS conference

Avita gel can now be launched in U.S.

Genetic basis for RP described

Favorable clinical safety, pharmacokinetics and anti-CMV activity reported for 1263W94

Concrete terms of Receptagen-Scitech Genetics merger announced

Gene-based breast cancer test launched in U.S.

Salivary peptide fragment may be useful for oral candidiasis

Algos initiates FDA approval process for MorphiDex

Janssen obtains worldwide license to develop and market norastemizole

E.U. gives stamp of approval to Roche acquisition of Corange

Cytel and Baxter extend xenotransplantation agreement

Early clinical results support potential of ABT-378/ritonavir combination

Another name change for BioDx

Biomet-Merck orthopedic joint venture

Multiple-dose phase I trial of FP-21399 in HIV discussed at AIDS conference

New anti-PCP agent is more potent than pentamidine

PNU-140690: clinical pharmacokinetics and safety after single and multiple doses

Seragen fusion toxin will get priority review

Penederm and Alpharma enter marketing agreement

NIF is neuroprotective in rat model of ischemia

Pharmacokinetics and drug interactions for Fortovase

FddA demonstrates anti-HIV activity at well-tolerated doses in phase I trial

Zestril introduced for new indication in U.K.

CardioGenesis receives EU approval to market cardiovascular device

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...